NCT03871517View on ClinicalTrials.gov

INdobufen Versus aSpirin in acUte Ischemic stRokE,INSURE

PHASE4CompletedINTERVENTIONAL
Enrollment

5,438

Participants

Timeline

Start Date

June 3, 2019

Primary Completion Date

March 1, 2022

Study Completion Date

December 1, 2022

Conditions
Ischemic StrokeIndobufenAspirin
Interventions
DRUG

Indobufen

Indobufen inhibits platelet aggregation by reversibly inhibiting the platelet cyclooxygenase enzyme thereby suppressing thromboxane synthesis.

DRUG

Aspirin

Aspirin is a salicylate (sa-LIS-il-ate). It works by reducing substances in the body that cause pain, fever, and inflammation.

Trial Locations (1)

100050

Beijing Tian Tan Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Beijing Tiantan Hospital

OTHER

NCT03871517 - INdobufen Versus aSpirin in acUte Ischemic stRokE,INSURE | Biotech Hunter | Biotech Hunter